A cannabis operator with assets in the international cannabis market confirmed the sale of its South American and Caribbean interests to a major Canadian licensed producer.

In a deal announced on Tuesday (July 17) Scythian Biosciences (TSXV:SCYB) will sell its entire network of cannabis businesses across Argentina, Colombia and Jamaica to Aphria (TSX:APH) through the share acquisition of LATAM Holdings for a reported C$193 million worth in Aphria’s stock issued to Scythian.


“This timely strategic move allows Aphria to leverage Scythian’s first mover progress in the region while expanding on their own global reach and scope,” Scythian CEO Rob Reid said.

“We have spent a considerable amount of time and resources evaluating opportunities in Latin America and the Caribbean and we are confident in the long-term strategic opportunity and the value it will bring to our shareholders,” Vic Neufeld, CEO of Aphria said in a statement.

In addition to purchasing the assets from Scythian through LATAM Holdings’ share acquisition, Aphria will also assume a US$1 million debt bill.

Scythian indicated it obtained an opinion from Haywood Securities saying the value for LATAM Holdings was in the range of C$180 million to C$200 million.

A simple majority of Scythian shareholders must approve the transaction at a meeting the company said will schedule before September 15. The board of directors for the company unanimously approved the Aphria deal and recommended shareholders to vote in favor of it.

Both Scythian and Aphria suffered dips in share price during Tuesday’s trading session following the announcement of this transaction. Scythian’s shares took the bigger hit today as its stock declined in value 20.40 percent, a C$1.01 loss per share for investors, and closed at a price of C$3.94. While Aphria dropped 3.35 percent to a price of C$10.42.

What does Aphria get with this purchase?

If the transaction gets completed, Aphria is eyeing the potential of adding variety of businesses and licenses for cannabis ventures throughout South America.

In Colombia Aphria will obtain a 90 percent stake in Colcanna, a local medical cannabis producer with licenses for the extraction, production, research and exportation of medical cannabis products and importing cannabidiol (CBD).

Aphria will also get Argentinian pharmaceutical import and distribution company ABP, which holds a license for the import of CBD oil products and expands the potential reach of Aphria’s products through South America.

Schytian’s assets will also offer Aphria an entry into the Jamaican market thanks to obtaining Marigold Acquisitions, a company with a 49 percent stake in Marigold Projects Jamaica through wholly owned subsidiary Hampstead Holdings.

This Jamaican venture also holds a portfolio of beneficial licenses for the cannabis market in the country.

Investor takeaway

As the Canadian market keeps expanding with new players and operations appearing nearly  every week, some cannabis ventures –particularly larger public players– have started developing assets in international markets.

Throughout South America a cannabis movement is starting to appear for medical purposes; companies are starting to place bets in the developments of these markets as the promise of Canada leading the march on cannabis legalization solidifies.

In a previous interview with the Investing News Network (INN) Neil Closner, CEO of MedReleaf (TSX:LEAF), voiced an opinion strongly felt throughout observers of the industry: the international medical market is the biggest option available for all these companies.

“Many of those countries [advancing medical cannabis legalization policies] are more medically focused and medical rigorous than even Canada is today,” Closner told INN.

Similarly Alvaro Torres, CEO of Khiron Life Sciences (TSXV:KHRN) told INN LPs are looking for ways to “continue opening up their well-known strategies and well-known cultivation activities” in new markets.

This move also continues a trend of mergers and acquisitions within the cannabis space led by the larger companies in the public markets.

As part of INN’s Q2 2018 review of the cannabis sector, Yasmin Gordon, senior investment advisor with Canaccord Genuity, said she has noticed most of the big companies participating in the M&A activity are being clever in the capital raised leading to conscious business decisions in an attempt for these companies to hold their valuations.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editor’s Note: This story was updated to correct the share price and percentage drop for both companies involved in the story during stock during Tuesday’s trading session.

Editorial Disclosure: Khiron Life Sciences is a client of the Investing News Network. This article is not paid-for content.

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less